Thursday, 18 April 2024
Trending

[the_ad_group id="2845"]

Investing

TC BioPharm eyes expansion with CAR-NK technology LOI By Investing.com

Pinterest Climbs 2.25% By Investing.com

[the_ad id="21475"]

[ad_1]

EDINBURGH – TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a biotech firm specializing in gamma-delta T cell therapies, has announced its intention to acquire new assets to expand its therapeutic platform. The company signed a non-binding letter of intent (LOI) to potentially integrate two allogeneic CAR-NK (Chimeric Antigen Receptor Natural Killer) cell technologies into its portfolio, primarily aimed at solid tumor treatments.

The acquisition targets include a CD-70 CAR NK technology and an HER2 CAR-NK technology, which TC BioPharm believes could be effective as standalone treatments and in combination with its current investigational therapy, TCB-008. The company envisions clinical and manufacturing synergies through this move, leveraging its existing infrastructure and expertise to enhance the development of these technologies.

Natural Killer cells, part of the body’s innate immune response, are recognized for their potential in cancer therapy due to their ability to identify and destroy cancer cells without genetic modification, allowing for quicker patient treatment.

TC BioPharm has been granted an exclusive period to negotiate a definitive agreement, although there is no certainty that this will lead to a finalized deal or that the transaction will proceed within the anticipated timeframe. The completion of the proposed acquisition will be contingent upon various conditions, including board approval, sufficient financing, and regulatory consents.

CEO Bryan Kobel expressed optimism, viewing this as an opportunity to position TC BioPharm as a leader in cell therapy and enhance shareholder value. The proposed acquisition is expected to not only broaden the company’s cancer treatment options but also offer potential benefits to patients through expanded clinical trials.

TC BioPharm is recognized for its pioneering work in gamma-delta T cell therapies and is currently involved in clinical trials for treating acute myeloid leukemia. The information regarding this LOI is based on a press release statement from TC BioPharm.

InvestingPro Insights

As TC BioPharm (Holdings) PLC (NASDAQ: TCBP) explores the expansion of its therapeutic platform with the potential acquisition of novel CAR-NK cell technologies, the company’s financial health and market performance become crucial for investors monitoring the situation. TCBP’s strategic moves come at a time when the company’s financial data reflects significant challenges.

InvestingPro data indicates a market…

Click Here to Read the Full Original Article at All News…

[ad_2]

[the_ad id="21476"]